FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MANGANO ROSS J				2. Issuer Name and Ticker or Trading Symbol BIOSANTE PHARMACEUTICALS INC								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner						
(Last) (First) (Middle) 112 WEST FEFFERSON BOULEVARD SUITE 613				3. Da	bpa] 3. Date of Earliest Transaction (Month/Day/Year) 03/18/2004									Officer below)	(give tit	tle	Oth belo	er (specify ow)
(Street) SOUTH BEND		16634 Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicabl Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person												erson		
1. Title of Security (Instr. 3) 2. Transa Date		2. Transacti	ion 2A. Deemed Execution Date,		a. Securities Acquired (A) Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)			ed (A) or	5. Amount of Securities Beneficially Owned Following			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
					Code V		Amount	(A) or (D)	Price	Tran	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Common Stock			03/18/2	004				A		211(1)	A	(2)		29,30)4		D	
Common Stock													1	,314,0)27		I	BY JO & Co.
Common Stock	Common Stock													33,33	3		I	By Trust ⁽³⁾
Common Stock	ommon Stock										33,333		3	I		By Trust ⁽³⁾		
Common Stock														33,333			I	By Trust ⁽³⁾
Common Stock														100,000		I		Held as an Investment Advisor for an Individual ⁽⁴⁾
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)		on Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Expirat (Month	ion Da		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		8. Pric Deriva Securi (Instr.	tive d ty S 5) B O F R	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership	
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- 1. Mr. Mangano acquired these shares as a stock award for director compensation granted under BioSante Pharmaceutical's Amended and Restated 1998 Stock Plan.
- 3. Shares are held indirectly by Mr. Mangano in various trusts of which Mr. Mangano is the trustee.
- 4. Shares are indirectly held by Mr. Mangano as an investment advisor on behalf of an individual.

/s/ Ross Mangano, by Phillip B. Donenberg, attorney-in-fact

03/22/2004

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.